Araceli Biosciences Announces Matt Beaudet As New President And CEO

Araceli Biosciences, a pioneer in cell-based screening and analysis technologies, has announced a significant leadership change with the appointment of Matthew (Matt) Beaudet as the new Chief Executive Officer (CEO). With a career spanning over two decades, Matt Beaudet brings a wealth of experience from his time at several leading companies in the biotech sector, including Molecular Probes, Invitrogen, and Life Technologies. His most recent role as CEO of InVivo Biosystems saw him successfully navigate the company through substantial growth phases, marked by significant capital raises and the commercialization of innovative fluorescence-based assays and instrument platforms.

Bill Cortelyou, Chairman of the Board at Araceli, expressed the board's confidence in Beaudet's leadership abilities. He highlighted Matt's commitment to the Oregon biotechnology community, his entrepreneurial spirit, and his track record of fostering innovation and collaboration. Cortelyou is optimistic that Beaudet's direction will usher in a new era of growth and development for Araceli.

Upon his appointment, Beaudet shared his enthusiasm for joining Araceli Biosciences. He acknowledged the innovative success of Araceli's platform and expressed his honor in leading the team at such a pivotal moment. Beaudet is committed to transforming drug development processes and redefining possibilities within the biotech field.

Araceli Biosciences Inc. is dedicated to advancing technologies that enable researchers to expedite therapeutic discovery. The company aims to lead in predictive AI-based image acquisition and analysis, facilitating more informed decisions that enhance therapeutic success rates. Araceli envisions a future where effective treatments are accessible to patients sooner.

For further information about Araceli Biosciences and Matt Beaudet's vision for the company, visit www.aracelibio.com.